经会阴模板前列腺定位穿刺活检应用价值的综合评估:13年经验
回顾性分析杜克大学2009年8月至2021年1月共218例接受经会阴模板定位穿刺活检(TTMB)的患者,中位随访57个月。总体前列腺癌检出率72.9%,临床显著前列腺癌53.2%,并发症率17.4%(多为Clavien I级),功能评分影响轻微。作者认为TTMB有助于排除前列腺癌、避免过度治疗、评估局灶治疗资格及识别需全腺体治疗者。
要点
- 218例TTMB患者总体前列腺癌检出率72.9%,临床显著前列腺癌53.2%。
- 既往无前列腺癌诊断者(n=117)检出率64.1%,临床显著者49.5%。
- TTMB时正在主动监测者(n=86)中36例(41.8%)出现Gleason升级。
核心结论
- 在该队列中,TTMB提高了癌症检出率且对功能结局总体影响轻微。
- 作者认为TTMB有助于排除前列腺癌、避免可继续主动监测者的过度治疗、评估局灶治疗资格并识别需全腺体治疗者。
研究设计与样本
- 回顾性分析杜克大学2009年8月至2021年1月接受经会阴模板定位穿刺活检(TTMB)的患者,共218例,中位随访57个月。
- 功能结局采用国际勃起功能指数-5(IIEF-5)和国际前列腺症状评分(IPSS)评估,记录30天内并发症。
- 采用非参数统计分析比较基线至TTMB后2周和6周的功能指标。
主要发现
- 并发症率17.4%,其中大多数为Clavien I级。
- 总体前列腺癌检出率72.9%,临床显著前列腺癌53.2%。
- 既往无前列腺癌诊断者(n=117)总体检出率64.1%,临床显著前列腺癌49.5%。
- TTMB时正在主动监测者(n=86)中36例(41.8%)出现Gleason升级。
- TTMB改变了59例(68.6%)患者的管理,其中38例(44.2%)接受全腺体治疗,21例(24.4%)选择局灶治疗。
临床怎么用
- 作者认为TTMB有助于排除前列腺癌、避免可继续主动监测者的过度治疗、评估局灶治疗资格并识别需全腺体治疗者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess Duke's experience on the utility of transperineal template mapping biopsy (TTMB) for re-evaluating patients with persistently elevated prostate-specific antigen after prior negative biopsy, with pre-existing prostate cancer (PCa) already on active surveillance (AS), or considering focal therapy (FT). METHODS: We retrospectively reviewed Duke patients undergoing TTMB. Functional outcomes were evaluated using International Index of Erectile Function-5 (IIEF-5) and International Prostate Symptom Score (IPSS). Complications within 30 days were recorded. Nonparametric statistical analyses compared functional measures from baseline to 2 and 6 weeks post-TTMB. RESULTS: From 8/2009 to 1/2021, 218 patients underwent TTMB, with 57-month median follow-up. Complication rate was 17.4%, with the majority Clavien I. Overall PCa detection was 72.9%, with clinically significant PCa in 53.2%; for those without prior PCa diagnosis (n = 117), overall detection was 64.1% with clinically significant PCa in 49.5%. Of those on AS at TTMB (n = 86), 36 (41.8%) had Gleason upgrading. TTMB changed management for 59 (68.6%) patients, with 38 (44.2%) proceeding to whole-gland therapy and 21 (24.4%) electing FT. Regarding functional outcomes, IPSS were insignificantly different from baseline at 6 weeks (P = NS). Overall functional score impacts were minimal across subgroups; in groups with significant declines in IIEF-5, median score drops were ≤1 point and caused minimal/no movement in IIEF-5 scoring category. CONCLUSION: In this cohort, TTMB offered enhanced cancer detection with overall minimal impact to functional outcomes. We conclude from this comprehensive assessment that TTMB provides value to rule out PCa, prevent overtreatment of those that can remain on AS, evaluate FT candidacy, and identify those needing whole-gland management.
引用
- Michael ZD, Kotamarti S, Deivasigamani S, et al. A Comprehensive Assessment of the Utility of Transperineal Template Prostate Mapping Biopsy: A 13-year Experience. Urology. 2023. PMID: 37105359. doi:10.1016/j.urology.2023.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。